Serum levels of RANKL and OPG, and the RANKL/OPG ratio in bisphosphonate-related osteonecrosis of the jaw: Are they useful biomarkers for the advanced stages of osteonecrosis?
Med. oral patol. oral cir. bucal (Internet)
; 22(5): e542-e547, sept. 2017. tab
Article
in English
| IBECS
| ID: ibc-166647
Responsible library:
ES1.1
Localization: BNCS
ABSTRACT
Background:
We determined whether serum levels of Receptor Activator for Nuclear Factor κ B Ligand (RANKL), Osteoprotegerin (OPG), and the RANKL/OPG ratio could be useful biomarkers for the severity of oral lesions in bisphosphonate-related osteonecrosis of the jaw (BRONJ). Material andMethods:
A case-control study in which Group 1 consisted of 41 patients with BRONJ due to bisphosphonates, and Group 2 consisted of 44 healthy control cases. The plasma levels of RANKL and OPG were analyzed by an ELISA assay. The OPG/RANKL ratio was also calculated. We determined if the mean serum values differed among the different stages of BRONJ.Results:
Serum levels of RANKL were lower in Group 1 than in Group 2 (p =0.01), and serum levels of OPG were higher in patients with BRONJ than in the controls (p =0.006). The ratio of RANKL/OPG was greater in the controls than in Group 1 (p >0.01). There were no significant differences in the serum levels of RANKL and OPG among the different stages of osteonecrosis (p >0.05).Conclusions:
Serum levels of RANKL and OPG, and the RANKL/OPG ratio were not valuable biomarkers for determining the severity of oral lesions in patients with BRONJ (AU)RESUMEN
No disponible
Full text:
Available
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Diphosphonates
/
Bisphosphonate-Associated Osteonecrosis of the Jaw
Type of study:
Observational study
/
Risk factors
Limits:
Humans
Language:
English
Journal:
Med. oral patol. oral cir. bucal (Internet)
Year:
2017
Document type:
Article
Institution/Affiliation country:
Universidad Europea de Valencia/Spain
/
University General Hospital/Spain
/
Valencia University/Spain